GlassScriptPhysician profile
Chaitanya Pabbati
NPI 1710237391
$7,427.10
in general payments reported to CMS, 2019-2025
28 companies · $1,553 in 2025
The $1,553 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $660 · 2020: $194 · 2021: $1,090 · 2022: $1,481 · 2023: $1,106 · 2024: $1,344 · 2025: $1,553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,905 · Education: $98.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,904.64 |
| Education | $98.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,535.28 | 2019-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $1,015.97 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $757.08 | 2019-2025 | Rexulti |
| Abbvie INC. | $694.96 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $573.50 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $567.55 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $334.09 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $292.60 | 2019-2025 | Ingrezza |
| Indivior INC. | $215.85 | 2019-2025 | Sublocade |
| Vanda Pharmaceuticals INC. | $201.66 | 2019-2022 | |
| Tempus Ai, INC | $175.03 | 2024 | |
| Axsome Therapeutics, INC. | $140.82 | 2022-2025 | Auvelity |
| Corium, LLC | $118.57 | 2022-2024 | Azstarys |
| Alkermes, INC. | $109.79 | 2021-2025 | Aristada, Lybalvi |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $98.36 | 2024 | Rexulti |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $90.37 | 2025 | Spravato |
| Shire North American Group INC | $77.47 | 2019 | |
| Supernus Pharmaceuticals, INC. | $76.01 | 2022-2023 | Qelbree |
| Brainsway USA INC | $53.60 | 2025 | Deep Tms System |
| Livanova USA, INC. | $45.27 | 2022-2024 | Vns Therapy Symmetry Model 8103 Generator |
| Tris Pharma INC | $45.26 | 2023-2024 | Dyanavel Xr |
| Alfasigma USA, INC. | $43.43 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $43.02 | 2022 | |
| Ironshore Pharmaceuticals INC. | $38.08 | 2019-2020 | |
| Allergan, INC. | $31.83 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $21.29 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $15.37 | 2019 | |
| Bausch Health US, LLC | $14.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chaitanya Pabbati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.